Evidence map›Paper›PMID 37070065›Full record

ArticleClinicoEconomics and outcomes research : CEOR2023

Clinical and Economic Burden Associated with Prolonged Air Leaks Among Patients Undergoing Thoracic Resection: A Retrospective Database Analysis.

Barbara H Johnson, Stephen S Johnston, Pranjal Tewari, Mosadoluwa Afolabi, Walter Danker Iii

Registry-linked trialAbstract read
In one paragraph

Article in ClinicoEconomics and outcomes research : CEOR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07184528 (PATCHVALVE Trial), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07184528 narecruitingnot on this mapstarted 2025, after this paper: background citation

PATCHVALVE Trial: A Prospective Evaluation of Blood Patch and Endobronchial Valves for Persistent Air Leaks - Pilot Study

TypeinterventionalSponsorBeth Israel Deaconess Medical CenterRan2025 to 2027Enrolled20ConditionsPersistent Air LeaksArmsEndobronchial Blood Patch, Spiration Valve System (SVS) Placement
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Endoluminal approaches to postoperative air leaks.Journal of thoracic disease · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Barbara H JohnsonEpidemiology, Johnson & Johnson, New Brunswick, NJ, USA.ORCID 0000-0001-7973-8902
Stephen S JohnstonEpidemiology, Johnson & Johnson, New Brunswick, NJ, USA.
Pranjal TewariData Sciences, Mu Sigma, Bengaluru, Karnataka, India.
Mosadoluwa AfolabiEpidemiology, Johnson & Johnson, New Brunswick, NJ, USA.
Walter Danker IiiEthicon Franchise Health Economics and Market Access, Johnson & Johnson, Raritan, NJ, USA.ORCID 0000-0002-9741-5821

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Prophylactic use of lung sealants among patients undergoing thoracic resection has been reported for the management of intraoperative air leaks and is associated with a lower incidence of prolonged air leak (PAL) and a shorter length of stay (LOS). This study estimated the incremental economic and clinical burden of PAL among patients with lung sealants used during thoracic resection in the United States. Patients and Methods: This retrospective analysis examined hospital data (Premier Healthcare Database) for adults (age ≥18 years) with inpatient thoracic resection between October 2015 - March 2021 (first admission=index) and lung sealant used during their procedure. Follow-up extended through 90 days post-discharge. Patients were grouped by presence/absence of PAL (ie, diagnosis of post-procedural air leak or post-procedural pneumothorax with associated LOS exceeding 5 days). Outcomes included intensive care unit (ICU) days, total index hospital costs, all-cause 30-, 60-, and 90-day readmission, discharge status, and in-hospital mortality. Generalized linear models quantified associations between PAL and outcomes, accounting for hospital-level clustering, and patient, procedure, and hospital/provider characteristics. Results: Among the 9727 patients included for study (51.0% female, 83.9% white, mean age 66 years), 12.5% had PAL, which was associated with significant incremental increases in ICU days (0.93 days, p<0.001) and total hospital cost ($11,119, p<0.001). PAL also decreased the likelihood of discharge to home (from 91.3% to 88.1%, p<0.001) and increased the risk of readmission within 30, 60, and 90 days by up to 34.0% (from 9.3% to 12.6%;11.7% to 15.4%;13.6% to 17.2%, respectively), all p<0.01. Absolute risk of mortality was low, but two times higher in patients with PAL versus those without PAL (2.4% vs 1.1%, p=0.001). Conclusion: This analysis demonstrates that despite the prophylactic use of lung sealants, PAL continues to put a burden on the healthcare system, highlighting an unmet need for improved sealant technology.

Indexed as

healthcare resource utilizationhospital costslung sealantssurgical complications

Identifiers

PMID37070065
PMCPMC10105567

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.